197 results on '"Michelutti, Angela"'
Search Results
2. ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission
3. ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia
4. BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies
5. ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome
6. Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia
7. mpact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center
8. Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4+ and CD8+ T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
9. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
10. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients
11. Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia
12. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse
13. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
14. Case–control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
15. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins
16. Epstein-Barr Virus Reactivation in a Patient Treated with Anti-thymocyte Globulin for Severe Aplastic Anemia
17. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies
18. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia
19. Rituximab for the treatment of type II mixed cryoglobulinemia
20. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia
21. Efficacy and safety of rituximab in type II mixed cryoglobulinemia
22. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia
23. Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center.
24. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance
25. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells
26. Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4+and CD8+T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
27. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
28. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients
29. Efficacy and toxicity of fludarabine, AraC, and idarubicine versus idarubicine, AraC and etoposide for induction treatment of newly diagnosed acute myeloid leukemia in patients younger than 60 years
30. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse
31. Q141K Polymorphism of ABCG2 Protein Is Associated with Poor Prognosis In Adult Acute Myeloid Leukemia Treated with a Idarubicin-Based Chemotherapy Protocol
32. Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients
33. Quantitative assessment ofWT1gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia
34. Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial
35. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia
36. Cytokine Patterns and Lymphocyte Subsets in Patients with Chronic GVHD after Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning.
37. Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
38. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype
39. Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.
40. Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells.
41. Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and SCH66336) on Acute Leukemia Human Tumor Cell Lines.
42. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells
43. Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.
44. Antibody binding capacity for evaluation of MDR‐related proteins in acute promyelocytic leukemia: Onset versus relapse expression
45. Bodipy-FL-Verapamil: A Fluorescent Probe for the Study of Multidrug Resistance Proteins
46. Pregnancy and abortion in women with essential thrombocythemia
47. Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia
48. Amifostine Does Not Inhibit the Toxic Effects of Anthracycline Derivates or Mitoxantrone on MDR Tumor Cell Lines
49. Screening of Bcr-Abl Transcripts in Philadelphia Negative Essential Thrombocythemia
50. Screening for Multidrug Resistance in Leukemia: Cell Reactivity to MRK-16 Correlates with Anthracycline Retention and Sensitivity of Leukemic Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.